NAD+
nad nasal spray prescription
Do You Need a Prescription for NAD Nasal Spray?
Do you need an NAD nasal spray prescription? Arc-1's compounded spray needs one via telehealth; research sprays need none but are not for human use.
It depends on which NAD nasal spray you're referring to in terms of whether you need a prescription for one. The $149.99 Arc-1 can't be purchased without one from a doctor, while the $120.00 Real Peptides 1000mg product does not require a prescription since it is not intended for human use and is instead meant for research purposes.
This division perplexes many customers, and I can see why: both are referred to as NAD+ sprays and both of them can be sent to addresses in the US. The thing is explained on this page: the differences between the two legal options and how the telehealth process works, as well as information about compounding laws in 2026.
The Answer Depends on Which Product You Mean
Compounded NAD+ sprays for patients must be prescribed while research-grade sprays do not require a prescription. They are different products under different regulations.
| Question | Arc-1 NAD+ Nasal Spray | Real Peptides NAD+ Liquid Spray |
|---|---|---|
| Prescription required | Yes | No |
| Who it is sold for | Patients, after physician approval | Research use only |
| Who makes it | Compounding pharmacy | Research vendor, third-party COA |
| Medical guidance | From the prescriber | None |
| Price | $149.99, monthly subscription model | $120.00 |
The fact that researchers' spray can be obtained without NAD nasal spray prescription does not indicate that it’s a kind of product one can use for private consumption. The label indicates quite the opposite as FDA makes sure to read the label combined with the rest of the information provided by suppliers.
How the Arc-1 Telehealth Process Works
Arc-1 offers the telehealth service. The entire operation requires online medical intake and an appointment with a doctor. If any prescription comes from the doctor, the spray is prepared by a pharmacy and sent to your home.
It has been mentioned in the description of the offering that it is supervised by a physician with the product being referred to as pharmacy compounded. Arc-1 highlights that using this subscription service is a drawback due to the monthly fee charged. Also, they are providing 30-day returns and the same applies to their NAD+ injections which people can buy for $299.99.
The prescriber is also the person who decides whether NAD+ suits you and in what amount. That is the core reason the telehealth route exists. Our dosage page explains why amounts belong with the prescriber and not on a website.
Why a Research Spray Has No Prescription Step
Those selling AD+ products for research purposes do not regard themselves as prescribing medication. The products are marked as solely for research use and come without consultation.
That has consequences for the buyer. There is no doctor reviewing your health, no medical guidance, and no claim that the product is suitable for people. What a research vendor does provide is documentation: Real Peptides publishes a third-party COA for its spray and its $60.00 multi-dose vial.
FDA's 24 August 2026 warning letters to five online peptide vendors showed where the line sits. FDA said "research use only" labels do not decide the question, and that disease claims, dosing guidance, reconstitution calculators and bacteriostatic water sold beside injectables counted as evidence of intended human use. NAD+ was not among the products named in those letters.
Compounding Rules and the 503A Bulks List
Compounding pharmacies can only use bulk substances that fit FDA's rules, and the list of permitted substances for 503A pharmacies has been under review for peptides. NAD+ was not part of the 2026 panel votes.
On 23 and 24 July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six peptides to the 503A bulks list: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax. The votes are non-binding. FDA still has to decide and then go through proposed and final rulemaking with public comment. These votes do not change anything about NAD+ sprays, but they show how slowly the compounding framework moves.
The buyer's understanding of the situation is limited: a compounded spray offered at a telehealth service is within the prescription system, but in reality, none of the NAD+ sprays discussed in this site has been approved by the FDA.
Questions to Ask a Telehealth Prescriber
Those who write a prescription for NAD nasal spray might find useful questions concerning appropriateness, proofs and usage since that information is not covered in any informational list. We could also reflect on the following:
- What does the evidence show for NAD+ by the nasal route, given limited bioavailability data?
- Is NAD+ appropriate with my current medicines and health history?
- How is the monthly subscription billed and cancelled?
- What does the 30-day return term cover?
If you are comparing the prescription route with research products on price, our cost comparison runs the numbers, and the NAD+ nasal spray options page lines up every listed term. Your own doctor is also a good first stop before any telehealth intake.
📚 Deep dive
It depends on which NAD nasal spray you're referring to in terms of whether you need a prescription for one. The $149.99 Arc-1 can't be purchased without one from a doctor, while the $120.00 Real Peptides 1000mg product does not require a prescription since it is not intended for human use and is instead meant for research purposes.
This division perplexes many customers, and I can see why: both are referred to as NAD+ sprays and both of them can be sent to addresses in the US. The thing is explained on this page: the differences between the two legal options and how the telehealth process works, as well as information about compounding laws in 2026.
Compounded NAD+ sprays for patients must be prescribed while research-grade sprays do not require a prescription. They are different products under different regulations.
| Question | Arc-1 NAD+ Nasal Spray | Real Peptides NAD+ Liquid Spray |
|---|---|---|
| Prescription required | Yes | No |
| Who it is sold for | Patients, after physician approval | Research use only |
| Who makes it | Compounding pharmacy | Research vendor, third-party COA |
| Medical guidance | From the prescriber | None |
| Price | $149.99, monthly subscription model | $120.00 |
The fact that researchers' spray can be obtained without NAD nasal spray prescription does not indicate that it’s a kind of product one can use for private consumption. The label indicates quite the opposite as FDA makes sure to read the label combined with the rest of the information provided by suppliers.
Arc-1 offers the telehealth service. The entire operation requires online medical intake and an appointment with a doctor. If any prescription comes from the doctor, the spray is prepared by a pharmacy and sent to your home.
It has been mentioned in the description of the offering that it is supervised by a physician with the product being referred to as pharmacy compounded. Arc-1 highlights that using this subscription service is a drawback due to the monthly fee charged. Also, they are providing 30-day returns and the same applies to their NAD+ injections which people can buy for $299.99.
The prescriber is also the person who decides whether NAD+ suits you and in what amount. That is the core reason the telehealth route exists. Our dosage page explains why amounts belong with the prescriber and not on a website.
Those selling AD+ products for research purposes do not regard themselves as prescribing medication. The products are marked as solely for research use and come without consultation.
That has consequences for the buyer. There is no doctor reviewing your health, no medical guidance, and no claim that the product is suitable for people. What a research vendor does provide is documentation: Real Peptides publishes a third-party COA for its spray and its $60.00 multi-dose vial.
FDA's 24 August 2026 warning letters to five online peptide vendors showed where the line sits. FDA said "research use only" labels do not decide the question, and that disease claims, dosing guidance, reconstitution calculators and bacteriostatic water sold beside injectables counted as evidence of intended human use. NAD+ was not among the products named in those letters.
Compounding pharmacies can only use bulk substances that fit FDA's rules, and the list of permitted substances for 503A pharmacies has been under review for peptides. NAD+ was not part of the 2026 panel votes.
On 23 and 24 July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six peptides to the 503A bulks list: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax. The votes are non-binding. FDA still has to decide and then go through proposed and final rulemaking with public comment. These votes do not change anything about NAD+ sprays, but they show how slowly the compounding framework moves.
The buyer's understanding of the situation is limited: a compounded spray offered at a telehealth service is within the prescription system, but in reality, none of the NAD+ sprays discussed in this site has been approved by the FDA.
💬 Do You Need a Prescription for NAD Nasal Spray? — FAQ
Does the Arc-1 NAD+ nasal spray need a prescription?
Yes. Arc-1 requires an online medical intake and a physician's prescription before a pharmacy compounds the spray.
Why can research NAD+ sprays be bought without a prescription?
They are not sold as medicines. They are labelled for research use only and not for human consumption.
Was NAD+ part of the July 2026 compounding panel votes?
No. The panel voted on six other peptides, and those votes are non-binding recommendations.
⚡ Research peptides mentioned in this guide
NAD+
NAD+
